Publications by authors named "Dong-Ta Zhong"
Article Synopsis
- The study assessed the effectiveness and side effects of a combination chemotherapy regimen (paclitaxel, 5-fluorouracil, leucovorin - TFL) in treating advanced gastric cancer (AGC) in 113 patients.
- Out of the patients, 43.4% showed positive responses, with three complete responses and 46 partial responses, while others had stable or progressive disease.
- The therapy was manageable in terms of side effects, with the most common severe toxicities being leukopenia and neutropenia, and it demonstrated promising median overall survival of 14.1 months.
Purpose: This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with Paclitaxel (PTX) and Oxaliplatin (OXA) as first-line treatment for patients with advanced gastric cancer (AGC).
Methods: One hundred and seven patients with locally advanced or metastatic gastric adenocarcinoma received intravenous infusions of PTX at 135 mg/m and OXA at 85 mg/m on day 1 every 14 days.
Results: Among 107 patients enrolled, 9 patients could not be evaluated for a response because of the absence of any measurable lesions.
Purpose: This study evaluated the efficacy and toxicity of combination chemotherapy with paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin (POFL) in patients with recurrent or metastatic gastric cancer.
Methods: One hundred and thirty-eight patients with histologically confirmed recurrent or metastatic gastric adenocarcinoma were treated with the POFL regimen: paclitaxel at a dose of 135 mg/m as a 3-hour intravenous infusion on day 1, oxaliplatin 85 mg/m and leucovorin 400 mg/m as an intravenous infusion over 2 hours on day 1, followed by 5-fluorouracil 2,400 mg/m as an infusion over a 46-hour period on 3 consecutive days, in a 2-week cycle.
Results: Twelve patients could not be evaluated for response because of the absence of any measurable lesions or early discontinuation of therapy, so responses were assessed in 126 patients.
This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with S-1 and oxaliplatin (SOX) as first-line treatment in elderly patients with advanced gastric cancer. One hundred and twenty-nine patients with recurrent or metastatic gastric adenocarcinoma were treated with SOX; S-1 (40-60 mg depending on patient's body surface area) was given orally, twice daily on days 1 to 14 followed by a 7-day rest period, 130 mg/m(2) oxaliplatin was given as an intravenous infusion over 2-hours on day one. The cycle was repeated every three weeks.
View Article and Find Full Text PDFNon-Hodgkin's lymphoma (NHL) remains the second most common malignant complication in patients with human immunodeficiency virus (HIV) infection. Even though NHL is commonly chemosensitive to primary treatment, failure or relapse still occurs in a large number of patients. We conducted this retrospective study to evaluate the efficacy and safety of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related NHL (AIDS-NHL).
View Article and Find Full Text PDFObjective: To evaluate through retrospective analysis the efficacy and toxicity of combination chemotherapy with etoposide, vincristine, doxorubin and dexamethasone (EVAD) as second-line therapy in patients with advanced AIDS-related Kaposi's sarcoma (AIDS-KS) after failure of first-line chemotherapy.
Methods: Eighty-eight patients with poor-risk AIDS-KS were treated intravenously with combination chemotherapy with EVAD; etoposide at a dose of 100 mg/m(2) on three consecutive days, vincristine 1.4 mg/m(2) with a maximum single dosage of 2.